Helena Mumblat, PhD

Novocure
Portsmouth, NH

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 3546 - Preclinical efficacy of TTFields and PARP inhibitors in ovarian cancer models

  Monday, September 30, 2024
  8:00 AM – 9:00 AM ET

• 3547 - Tumor Treating Fields (TTFields) Augment the Efficacy of Cisplatin for Treatment of Cervical Cancer, In Vitro and In Vivo

  Monday, September 30, 2024
  8:00 AM – 9:00 AM ET